The materials used to fabricate pharmaceutical packaging components are extremely important to preserving the stability, efficacy and safety of drug formulations. In fact, according to the USFDA, in the last two years, there have been over 2,000 drug and device recalls owing to packaging-related ... Read more

Driven by the growing complexity of modern pharmacological interventions, industry stakeholders have developed container-closures systems using more versatile materials; in this context, elastomers have demonstrated significant potential

... Read more

Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests ... Read more

Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

... Read more

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid ... Read more

Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community

... Read more

Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries

... Read more

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel ... Read more